Providence care Hospital

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Bipolar disorder3 trials
• Depression3 trials
• Stroke2 trials
• Schizophrenia1 trial

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Completed3 trials
• Recruiting3 trials
• Not yet recruiting2 trials
• Suspended1 trial

Lead sponsor

• Janssen Research & Development, LLC2 trials
• atai Therapeutics, Inc.1 trial
• Felicia Iftene1 trial
• Queen's University1 trial
• Teresa Broers1 trial
• and 3 more

Running trials

• Not yet recruiting

  Transcranial Photobiomodulation for Bipolar Depression

  NCT07510646· Vielight Inc.· Source

• Recruiting

  A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  NCT07573176· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Supporting Re-engagement in Life: Coaching to Enhance Participation in Valued Activities Following Stroke

  NCT07759791· Queen's University· Source

  Contact: Esther Chang

• Not yet recruiting

  Therapeutic Improvement in People With Schizophrenia Undergoing tACS/CBTp (Transcranial Alternating Current Stimulation Applied Pre-cognitive Behavioral Therapy for Psychosis) Associated to Usual Medication Regimen

  NCT06889025· Felicia Iftene· Source

  Contact: Felicia Iftene

• Recruiting

  Cannabidiol for Bipolar Depression (CBD-BD)

  NCT05867849· Phase 3· University of British Columbia· Source

  Contact: Roumen Milev, MD (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bipolar disorder2 recruiting
• Depression1 recruiting
• Schizophrenia1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· atai Therapeutics, Inc.· Source

• Completed

  Effectiveness of the Dynavision Device to Improve Spatial Awareness After Brain Injury

  NCT05506241· Teresa Broers· Source

• Completed

  A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

  NCT05841030· Janssen Research & Development, LLC· Source